In summary, our results show that PSMA-targeted examination and treatment for PCa are being adopted at an unprecedented rate and have made great progress, indicating that precision treatment of PCa is expected to be achieved in the future. This evidence concerns the gene FOLH1 and posterior cortical atrophy.